CIGMA as a tool in the study of NIDDM.

CIGMA as a tool in the study of NIDDM.

Opis bibliograficzny
Główni autorzy:	Turner, R, Rudenski, A, Hosker, J, Matthews, DR, Levy, J, O'Rahilly, S
Format:	Journal article
Język:	English
Wydane:	1988

Podobne zapisy

Pathogenesis of NIDDM--a disease of deficient insulin secretion.
od: Turner, R, i wsp.
Wydane: (1988)

ASSESSMENT OF B-CELL FUNCTION AND INSULIN RESISTANCE IN TYPE-II DIABETES BY CONTINUOUS INFUSION OF GLUCOSE WITH MODEL ASSESSMENT (CIGMA)
od: Turner, R, i wsp.
Wydane: (1985)

MEASUREMENT OF INSULIN-RESISTANCE AND BETA-CELL FUNCTION - THE HOMA AND CIGMA APPROACH
od: Turner, R, i wsp.
Wydane: (1993)

Application of structural model of glucose-insulin relations to assess beta-cell function and insulin sensitivity.
od: Turner, R, i wsp.
Wydane: (1990)

The glucose stimulus-response curve of the beta-cell in physically trained humans, assessed by hyperglycemic clamps.
od: O'Rahilly, S, i wsp.
Wydane: (1988)

Metabolic abnormalities in children of non-insulin dependent diabetics.
od: O'Rahilly, S, i wsp.
Wydane: (1986)

Evaluation of insulin sensitivity: the HOMA and CIGMA models
od: Levy, J
Wydane: (1998)

[Evaluation of insulin sensitivity: the HOMA and CIGMA models]
od: Levy, J
Wydane: (1998)

Quantitative modelling of endocrine diseases as exemplified by diabetes.
od: Turner, R, i wsp.
Wydane: (1987)

Does type II diabetes arise from a major gene defect producing insulin resistance or beta cell dysfunction?
od: Turner, R, i wsp.
Wydane: (1989)

Diabetes nomenclature: classification or grading of severity?
od: Turner, R, i wsp.
Wydane: (1986)

Segregation analysis of NIDDM in Caucasian families.
od: Cook, J, i wsp.
Wydane: (1994)

ESTIMATION OF INSULIN-SECRETION RATE BY DECONVOLUTION ANALYSIS OF C-PEPTIDE AND OF INSULIN GIVES CONSISTENT RESULTS
od: Rudenski, A, i wsp.
Wydane: (1986)

The beta cell glucose stimulus-response curve in normal humans assessed by insulin and C-peptide secretion rates.
od: Rudenski, A, i wsp.
Wydane: (1988)

Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy.
od: Hosker, J, i wsp.
Wydane: (1989)

Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes.
od: O'Rahilly, S, i wsp.
Wydane: (1988)

No glycemic benefit from guar administration in NIDDM.
od: Holman, R, i wsp.
Wydane: (1987)

Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy.
od: Rachman, J, i wsp.
Wydane: (1997)

Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.
od: Matthews, DR, i wsp.
Wydane: (1985)

Post-prandial amylin concentrations are increased by sulphonylurea, but unchanged by basal insulin, in NIDDM
od: Rachman, J, i wsp.
Wydane: (1996)

Insulin use in NIDDM. Rationale based on pathophysiology of disease.
od: Turner, R, i wsp.
Wydane: (1990)

Risk factors predicting progression of diabetic retinopathy over six years in 1579 NIDDM patients
od: Stratton, I, i wsp.
Wydane: (1996)

Leucine is a better priming agent than arginine for insulin secretion in gliclazide treated NIDDM
od: Matthews, DR, i wsp.
Wydane: (1997)

RESTING THE BETA-CELLS WITH INSULIN IN NIDDM DOES NOT IMPROVE BETA-CELL FUNCTION NOR PROINSULIN PROCESSING
od: Rachman, J, i wsp.
Wydane: (1995)

No evidence for excess allele-sharing on chromosome 2q (region of NIDDM1) in a large sibship collection
od: Cassell, P, i wsp.
Wydane: (1997)

Familial association and lambda s for diabetes, obesity, high triglycerides and low HDL-cholesterol in sibs of NIDDM patients
od: Levy, J, i wsp.
Wydane: (1997)

Familial association and lambda s for diabetes, obesity, high triglycerides and low HDL-cholesterol in sibs of NIDDM patients.
od: Levy, J, i wsp.
Wydane: (1997)

Treatment of NIDDM - Progressive requirement for polypharmacy to attain glycaemic goals
od: Cull, C, i wsp.
Wydane: (1997)

LOSS OF NORMAL SIGMOID, BETA-CELL DOSE-RESPONSE CURVE TO GLUCOSE IN NON-INSULIN-DEPENDENT DIABETES
od: Hosker, J, i wsp.
Wydane: (1984)

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.
od: Rachman, J, i wsp.
Wydane: (1997)

Continuous infusion of glucose with model assessment: measurement of insulin resistance and beta-cell function in man.
od: Hosker, J, i wsp.
Wydane: (1985)

Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM.
od: Rachman, J, i wsp.
Wydane: (1998)

An appreciation of Robert Turner.
od: O'Rahilly, S, i wsp.
Wydane: (2008)

Effects of ethnicity on metabolic control during the first six years of NIDDM
od: Davis, T, i wsp.
Wydane: (1997)

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
od: Rachman, J, i wsp.
Wydane: (1996)

A STUDY OF MOXONIDINE’S METABOLIC EFFECTS IN PATIENTS WITH ARTERIAL HYPERTENSION AND NIDDM
od: D. V. Nebieridze, i wsp.
Wydane: (2001-04-01)

Unsteady Natural Convection in a Cylindrical Containment Vessel (CIGMA) With External Wall Cooling: Numerical CFD Simulation
od: Ari Hamdani, i wsp.
Wydane: (2020-07-01)

UK prospective diabetes study (UKPDS) 14: association of angiotensin-converting enzyme insertion/deletion polymorphism with myocardial infarction in NIDDM.
od: Keavney, B, i wsp.
Wydane: (1995)

Coronary heart disease and risk factors in NIDDM--experience from the United Kingdom Prospective Diabetes Study.
od: Turner, R, i wsp.
Wydane: (1997)

Understanding "insulin resistance": both glucose resistance and insulin resistance are required to model human diabetes.
od: Rudenski, A, i wsp.
Wydane: (1991)